Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213.

被引：2
|
作者：
Coleman, Robert L.
Brady, Mark F.
Herzog, Thomas J.
Armstrong, Deborah Kay
Sabbatini, Paul
Walker, Joan L.
Kim, Byoung
Fujiwara, Keiichi
Tewari, Krishnansu Sujata
O'Malley, David M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Roswell Pk Canc Inst, NRG Stat & Data Ctr, Buffalo, NY USA
[3] Univ Cincinnati, Inst Canc, Div Gynecol Oncol, Cincinnati, OH USA
[4] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Weill Cornell Med Coll, New York, NY USA
[7] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[8] Sungkyunkwan Univ, Sch Med, Dept Obstet & Gynecol, Samsung Med Ctr, Seoul, South Korea
[9] Saitama Med Univ, Int Med Ctr, Hidaka, Japan
[10] UC Irvine Med Ctr, Orange, CA USA
[11] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5523
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5523
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer
    Gubbi, Ajit
    Kendrick, James E.
    Finkler, Neil J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (10) : 1105 - 1113
  • [2] Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer
    Kim, Se Ik
    Lee, Eun Ji
    Lee, Maria
    Chung, Hyunhoon
    Kim, Jae-Weon
    Park, Noh Hyun
    Song, Yong-Sang
    Kim, Hee Seung
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (12) : 1943 - 1950
  • [3] Benefit for female Patients: Bevacizumab in recurrent Platinum-sensitive Ovarian Cancer
    Schmalfeldt, Barbara
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2013, 51 (01): : A7 - A8
  • [4] Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
    Della Pepa, Chiara
    Banerjee, Susana
    ONCOTARGETS AND THERAPY, 2014, 7 : 1025 - 1032
  • [5] A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer
    Eisenhauer, E.
    Zanagnolo, V.
    Cohn, D.
    Salani, R.
    O'Malley, D.
    Sutton, G.
    Cobb, B.
    Vaughan, M.
    Fowler, J.
    Copeland, L.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S31 - S31
  • [6] A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer
    Eisenhauer, Eric L.
    Zanagnolo, Vanna
    Cohn, David E.
    Salani, Ritu
    O'Malley, David M.
    Sutton, Gregory
    Callahan, Michael J.
    Cobb, Bobbi
    Fowler, Jeffrey M.
    Copeland, Larry J.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (02) : 262 - 266
  • [7] Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer
    O'Malley, David M.
    Myers, Tashanna
    Wimberger, Pauline
    Gorp, Toon Van
    Redondo, Andres
    Cibula, David
    Nicum, Shibani
    Rodrigues, Manuel
    Backes, Floor J.
    Barlin, Joyce N.
    Lewin, Sharyn N.
    Lim, Peter
    Pothuri, Bhavana
    Diver, Elisabeth
    Banerjee, Susana
    Lorusso, Domenica
    FUTURE ONCOLOGY, 2024,
  • [8] Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
    Bartoletti, Michele
    Pelizzari, Giacomo
    Gerratana, Lorenzo
    Bortot, Lucia
    Lombardi, Davide
    Nicoloso, Milena
    Scalone, Simona
    Giorda, Giorgio
    Baldassarre, Gustavo
    Sorio, Roberto
    Puglisi, Fabio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11)
  • [9] Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study-Analysis of patient reported outcomes (PRO) on chemotherapy randomization.
    Basen-Engquist, Karen
    Huang, Helen Q.
    Herzog, Thomas J.
    Armstrong, Deborah Kay
    Sabbatini, Paul
    Walker, Joan L.
    Kim, Byoung Gie
    Fujiwara, Keiichi
    Tewari, Krishnansu Sujata
    O'Malley, David M.
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Platinum-free Interval May Predict Duration of Maintenance Bevacizumab and Survival in Platinum-sensitive Recurrent Ovarian Cancer
    Oh, Soo hyun
    Park, Soo jin
    Lee, Seungmee
    Lee, Seungho
    Kim, Hee seung
    IN VIVO, 2024, 38 (01): : 467 - 473
12345